Nkarta to Participate at Upcoming Investor Conference

SOUTH SAN FRANCISCO, Calif., May 31, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at an upcoming investor conference:

Cowen 3rd Annual Oncology Innovation SummitJune 2, 202211:00 a.m. ET – fireside chat

A simultaneous webcast of the event will be available on the Investors section of Nkarta’s website, www.nkartatx.com, and a replay will be archived on the website for approximately four weeks.

About NkartaNkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for cancer patients. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep anti-tumor activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company’s website at www.nkartatx.com.

Nkarta Media/Investor Contact:Greg MannNkarta, Inc.[email protected]

You May Also Be Interested In

• TD Cowen Starts Nkarta Inc. (NKTX) at Buy
• Metalsource Mining Continues to Expand High Grade Corridor at Silver Hill with Successful Step Out Drilling
• Adcore Announces Voting Results from Annual Shareholders Meeting